Immediate Impact
37 standout
Citing Papers
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
2024 Standout
Myasthenia gravis: the changing treatment landscape in the era of molecular therapies
2024 Standout
Works of Kerri Prain being referenced
AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD
2019
Use and monitoring of low dose rituximab in myasthenia gravis
2010
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Kerri Prain | 234 | 95 | 6 | 44 | 16 | 313 | |
| Verena Kraus | 211 | 214 | 3 | 26 | 12 | 323 | |
| Arlette L. Bruijstens | 183 | 152 | 7 | 18 | 12 | 258 | |
| P. Adam | 114 | 120 | 9 | 29 | 26 | 285 | |
| Andrew Swayne | 138 | 98 | 4 | 18 | 19 | 295 | |
| Eva‐Maria Wendel | 202 | 184 | 10 | 13 | 22 | 330 | |
| Joanna Tarasiuk | 80 | 138 | 21 | 27 | 28 | 284 | |
| Allen D. DeSena | 195 | 44 | 4 | 34 | 14 | 352 | |
| Davood Fathi | 133 | 76 | 46 | 20 | 25 | 294 | |
| Tim Lotze | 178 | 190 | 13 | 19 | 11 | 292 | |
| Bo Sun | 226 | 178 | 5 | 10 | 20 | 363 |
All Works
Loading papers...